This meta-analysis reports on current estimates of the prevalence of age-related macular degeneration (AMD) based on a review of recent meta-analyses and literature research. Within an age of 45-85 years, global prevalences of any AMD, early AMD, and late AMD were 8.7% 
D
ue to longer life expectancy and general ageing of populations, maculopathies and in particular age-related macular degeneration (AMD) have markedly increased in their importance as causes of irreversible visual impairment and blindness within the past 2 decades.
1-48 As a progressive chronic disease of the central retina, AMD leads to visual loss mostly in its medium-advanced and late stages due to a loss of retinal pigment epithelium cells and closure of the choriocapillaris in eyes with geographic atrophy and/or due to a scar formation in the macular region in association with a choroidal neovascularization in the foveal region. These changes result in a central relative or absolute scotoma, though the peripheral visual field is usually not affected. 49 Since landmark clinical trials demonstrated the therapeutic benefit of intravitreally applied antibodies against vascular endothelial growth factor (VEGF) in 2006, repeated intravitreal injections of ranibizumab, bevacizumab, aflibercept, and conbercept significantly improved vision in patients treated as compared with untreated patients of control groups. [50] [51] [52] Correspondingly, recent population-based data have suggested that legal AMD-related blindness has been reduced by 50% in some countries since the introduction of VEGF antagonists. 53, 54 Population-based investigations have revealed that age-related macular degeneration as the most common form of maculopathy is a major cause of vision loss in elderly people and that it shows a steep increase in its prevalence beyond an age of 75 years. 3, 8, 13, 23, 25, 42 The meta-analysis conducted by Wong and colleagues 42 suggested that AMD, as the most common cause of blindness in developed countries, was responsible for 8.7% of all global blindness. The present study was undertaken to summarize and update the findings obtained in previous studies.
materials and methods
For the meta-analyses that formed the main basis of this report, and also for the search performed for this report itself, articles reporting on the prevalence of AMD were looked for using the electronic databases of PubMed, Web of Science, and Embase. Search words applied were macular degeneration, age-related maculopathy or macular degeneration, and prevalence or epidemiology or cross-sectional studies or cohort studies. That search strategy was also employed in the previous landmark study performed by Wong and associates on the same topic in 2014. 42 In addition, the results of the Global Vision Database were used as another pillar of this report. 35, 36, 47, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] The Global Vision Database of the Vision Loss Expert Group is based on articles published between 1980 and 2015 as described in detail previously. 35, 36 As also reported previously, trends in the causes of vision impairment were estimated. This included uncertainties, stratified by age, sex, and geographical region. One differentiated among 21 regions globally as defined by the Global Burden of Disease Study.
results
The number of individuals affected by AMD was estimated in the landmark study by Wong and colleagues.
42 That meta-analysis The meta-analysis by Wong and colleagues 42 estimated that the projected number of individuals with AMD would be 196 million (95% CrI, 140-261) in the year 2020 and 288 million (95% CrI, 205-399) in the year 2040. Per geographical region, the number of patients afflicted by AMD in the year 2040 was expected to be highest in Asia (113 million; 95% CrI, 60-203), followed by Europe (69 million; 95% CrI, 40-109), Africa (39 million; 95% CrI, 12-93), Latin America and the Caribbean (39 million; 95% CrI, 15-82), North America (25 million; 95% CrI, 15-38), and finally Oceania (2 million; 95% CrI, 1-5).
The number of persons being blind or visually impaired due to AMD was estimated in the meta-analysis performed by the Vision Loss Expert Group for the year 2010.
35,36 Macular diseases, namely AMD, were the cause of blindness (defined as presenting visual acuity worse than 3/60) for 2.1 million [95% uncertainty interval (UI), 1.9-2.7] individuals out of 32.4 million blind individuals worldwide, and AMD was the cause for moderate to severe vision impairment (MSVI; defined as presenting visual acuity worse than 6/18 to 3/60 inclusive) in 6.0 million (95% UI, 5.2-8.1) persons out of 191 million people with moderate to severe visual impairment.
62 The increase in the number of persons being blind due to macular diseases from 1990 to 2010 was 36% (or 0.6 million), and the increase in the number of visually impaired persons was 81% (or 2.7 million). Because the global population increased by 30% during the period from 1990 to 2010, the increase in the number of people affected by AMD was mainly due to the increase in population and, additionally, due to ageing of the population. Correspondingly, the world population aged 50+ years increased by 60%; the number of people aged 50+ years and blind due to macular diseases increased by 31% from 1.6 million in 1990 to 2.1 million in 2010, and the number of individuals with MSVI caused by macular diseases increased by 62% from 3.3 million in 1990 to 6.0 million in 2010. 62 In 2010, macular diseases, namely AMD, were the cause of blindness in 6.6% of all blind individuals and were the cause for MSVI in 3.1% of all visually impaired persons. 62 The proportion of blindness caused by macular diseases including AMD showed a geographic variation. It was lowest in South Asia (<3%) and highest in high-income Asia-Pacific countries (19.5%), followed by southern Latin America (19.5%), Australasia (17.7%), high-income North America (16.4%), and Western Europe (16.1%). In a parallel manner, Australasia (8.0%) showed the highest proportion of MSVI caused by macular diseases, followed by Central Europe (7.4%), southern Latin America (7.2%), high-income Asia-Pacific countries (6.0%), high-income North America (5.5%), and finally South and Southeast Asia (<2%) and the Caribbean (<2%). This ranking followed the tendency that world regions with older populations, such as the high-income regions and southern Latin America, as compared with world regions with younger populations showed a higher percentage of blindness and MSVI caused by macular diseases, namely AMD.
62
In the year 2010 as compared with the year 1990, the percentage of blindness and of MSVI related to macular diseases, namely AMD, as compared with all causes of blindness and MSVI increased globally from 4.9% to 6.6% and from 1.9% to 3.1%, respectively. With the exception of Western Europe and high-income North America with constant figures, most other world regions experienced an increase in the proportion of global blindness and MSVI caused by macular diseases, namely AMD, in the period from 1990 to 2010. A recent meta-analysis performed by the Vision Loss Expert Group revealed that in the year 2015 AMD was the fourth most common cause of blindness (defined as presenting visual acuity less than 3/60 in the better eye) globally (causing blindness in approximately 5.8% of blind individuals) after cataract, undercorrection of refractive errors, and glaucoma (unpublished data). The estimated figures for 2020 suggested a similar ranking. In the ranked list of causes of MSVI (defined as visual acuity in the better eye lower than 6/18 but at least 3/60 at presentation), AMD ranked third (3.9%) after undercorrected refractive error and cataract, and it was followed by glaucoma (unpublished data).
discussion
The analysis of the existing literature and recent meta-analyses of the prevalence of AMD revealed that, within an age range of 45-85 years, the global prevalence of any type of AMD was approximately 8.7%, with the prevalence of early AMD being 8.0% and the prevalence of late AMD being 0.4%. Early AMD was more common in individuals of European ancestry than in Asians or in Africans, whereas the prevalence of the late stage of AMD did not differ significantly between Europeans and Asians. In individuals of African ancestry, the prevalence of any AMD was lowest. A marked increase in the prevalence of late AMD was noted for the age group of 75+ years, in particular in individuals Epidemiology of AMD of European descent. Globally, the number of individuals affected by AMD was forecasted to increase to 196 million in 2020 and to 288 million in the year 2040. 42 In 2010, AMD (besides other macular diseases) was the cause of blindness or MSVI in 2.1 million individuals out of 32.4 million blind individuals worldwide and 6.0 million persons out of 191 million people with MSVI. Age-standardized prevalence of macular diseases, namely AMD, as a cause of blindness in adults aged 50+ years worldwide decreased from 0.2% in 1990 to 0.1% in 2010, and as a cause for MSVI, it remained mostly unchanged at a value of 0.4%, with no significant difference between men and women. In 2015, AMD was the fourth most common cause of blindness globally (causing blindness in approximately 5.8% of blind individuals) after cataract, undercorrection of refractive errors, and glaucoma. It was the third most common cause for MSVI (3.9%) after undercorrected refractive error and cataract.
The ethnic difference in the prevalence of AMD as summarized in the present study is in agreement with previous studies, such as the Baltimore Eye Study or another multiethnic population-based study in the USA, which showed a significantly lower prevalence of any type of AMD in individuals of African ancestry than in people of European ancestry. 16, 26 In the Baltimore Eye Study, persons of European ancestry were more likely to have early and late AMD than those of African ancestry.
11 Two metaanalyses conducted in populations of European and Asian ancestry suggested that among persons aged 40-79 years, the agespecific prevalence of late AMD was similar in Asians (0.56%) and Europeans (0.59%), whereas early AMD was less common among Asians (6.8%) than in Europeans (8.8%).
25,31
Sex was not markedly associated with the prevalence of AMD or with the frequency of AMD as a cause for vision impairment or blindness. In some previous studies, female sex was considered a weak risk factor for late AMD.
63,64 The finding of the present study summarizing previous meta-analyses agrees with the results of previous investigations on individuals of European ancestry, who did not show a significant sex difference in the prevalence of neovascular age-related macular degeneration or geographic atrophy.
65 It is also in agreement with other studies on Asians.
14,21,22
The global overall increase in the number of people affected by blindness due to AMD, despite the reduction in its age-adjusted prevalence, was due to the worldwide demographic transition with increasing population size, substantial increase in the average age in most regions, and falling death rates.
66 As the drop in the age-standardized prevalence of macular degeneration-related blindness by 50 relative percent took place mostly in the high-income regions, one may infer that it was due to the clinical introduction of intravitreally applied anti-VEGF drugs.
50-53 Corresponding to the decrease in the age-standardized prevalence of macular degeneration-related blindness, the high-income regions of North America and Western Europe showed a stable percentage of blindness caused by macular degeneration in the period from 1990 to 2010, whereas most other regions experienced an increase. The reduction in the age-standardized prevalence of macular degeneration-related blindness (and the stable figures for visual impairment) was markedly less profound than the global decrease in the age-standardized prevalences of blindness due to cataract, undercorrected refractive error, and trachoma.
35,62
The increasing number of patients with late AMD, in particular neovascular AMD, will markedly increase the necessity of sufficient financial funds to treat this stage of the disease as is currently performed by intravitreal application of anti-VEGF. Future developments will show whether a more common use of inexpensive bevacizumab in an off-label fashion and/or the expiration of patent rights for ranibizumab and other approved drugs in several years will have an effect on the general availability of this hitherto only proven treatment for neovascular AMD. In that context, it may also be of interest that the steepest rise in the number of patients with late AMD will be in Asia due to the foreseeable demographic development. The future increase in the prevalence of AMD may be most marked in regions that actually have a relatively young population and where ageing of the population has just started, in contrast to regions that already now have a relatively old population. One may also consider that the impact of anti-VEGF therapy in these areas in Asia where polypoidal choroidal vasculopathy is a predominant subtype is less certain.
From 1990 onwards, the percentage of individuals blind or visually impaired due to AMD in comparison with the total number of blind or visually impaired people has continuously increased, reflecting the success in reducing the amount of blindness and vision impairment due to cataract and refractive error. Preliminary data as assessed by the Vision Loss Expert Group revealed that in the year 2015 AMD was globally the fourth most common cause of blindness and the third most common cause of MSVI. This shows the future importance of AMD for public health. If one anticipates that treatment modalities may also become available for the nonexudative forms of AMD, for which currently no treatments exist, the treatment costs for AMD may further increase in future. Several therapies directed against geographic atrophy as one form of late AMD are currently under development, and their potential impact on the incidence of blindness due to geographic atrophy of the macula will need to be evaluated in future studies.
Limitations of our study should be mentioned. First, most primary studies did not differentiate reliably between polypoidal choroidal vasculopathy and exudative age-related macular degeneration, which upon ophthalmoscopy can have a similar appearance. This might have led to an overestimation of the prevalence of late AMD in the Asian subgroup in the present study, as polypoidal choroidal vasculopathy is more common in Asians than in Europeans. 44, 45, 67 Second, by the same token, some studies did not clearly differentiate between AMD and myopic maculopathy as causes for blindness or vision impairment. Again, this might have led to an overestimation of AMD as a cause for blindness or vision impairment. Third, a major limitation was that many country-years remained without data or only had subnational data. Only a few national studies reporting vision impairment for all ages and all causes including AMD were available. Fourth, another limitation was that the number of patients with late AMD was relatively small in the primary studies, so that the statistical power of the statistical analysis was limited. Fifth, some population-based studies reported only the major cause of blindness or vision impairment so that in an individual with cataract and AMD, only cataract might have been noted as the cause of vision impairment. Additionally, in eyes with dense cataract, lens opacification might have prevented a clear examination of the fundus and the detection of concomitant AMD. This may have resulted in an underestimation of the prevalence of AMD.
In conclusion, these data show the increasing global importance of AMD as a visually disabling disease, which may be more common in individuals of European descent than in Asians or in people of African ancestry. In particular, the prevalence of late AMD showed a nonlinear increase after the age of 75 years, in particular in people of European descent. The percentage of AMD in total blindness and MSVI was higher in high-income regions with relatively older populations. In view of the globally ageing population, it is expected that the prevalence of AMD as a blinding disease will increase, in particular in regions with a still relatively young population. The stable prevalence of macular degeneration-related blindness and MSVI in some high-income regions despite increasing ageing might have been due to the therapeutic success of intravitreal medication. 
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